Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eli Lilly and Company,St Jude Children's Research Hospital
Scientific Title
Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors